MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Medpace Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$619.66+1.19 (+0.19%)
Close on Oct 19, 2026
- Market cap
- $17.69B
- P/E (TTM)
- 36.3
- Dividend yield
- –
Share price
+$91.59 (+17.34%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Medpace Holdings, Inc. grew revenue 24.7% to $2.78B over the twelve months to Jun 30, 2026. Operating income rose 22.2% to $583.40M, moving the operating margin from 21.4% to 21.0%. Free cash flow was $706.69M, up 21.9% from a year earlier.
Revenue
$2.78B
+24.7% vs. a year earlier
Operating income
$583.40M
+22.2% vs. a year earlier
Free cash flow
$706.69M
+21.9% vs. a year earlier
EPS, diluted
$17.05
+26.8% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $17.69B
- P/E ratio
- 36.3
- Price to sales
- 6.36
- Price to book
- 40.78
- Dividend yield
- –
- Free cash flow yield
- 3.99%
Fundamentals
- Revenue
- $2.78B
- Net income
- $491.50M
- EPS, diluted
- $17.05
- Free cash flow
- $706.69M
- Book value per share
- $15.19
- Diluted shares
- 29M
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
$2.78B+24.7% YoY
Operating income
$583.40M+22.2% YoY
Net income
$491.50M+17.5% YoY
EPS, diluted
$17.05+26.8% YoY
Free cash flow
$706.69M+21.9% YoY
Reported periodTrailing twelve months